Kyverna Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kyverna Therapeutics, Inc. (KYTX) on May 14, 2026, with the earliest event reported on the same date. The filing discloses significant changes to the Company's executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the transition of the former CFO to an advisory role.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Appointment of CFO: Gregory Martini was appointed as Chief Financial Officer, effective May 18, 2026. He will serve as the principal financial and accounting officer.
- Departure of Former CFO: Marc Grasso, M.D., ceased serving as CFO effective May 18, 2026. The departure is not due to any disagreement regarding operations, policies, or financial reporting.
- Transition Arrangement: Dr. Grasso will serve as a strategic advisor from May 18, 2026, through August 1, 2026, to ensure a seamless transition.
Compensation, Outlook, and Risks
New CFO Compensation (Gregory Martini):
- Base Salary: $525,000 annualized.
- Performance Bonus: Target of 40% of base salary (pro-rated for 2026).
- Sign-on Bonus: $300,000 total ($150,000 paid shortly after the effective date; $150,000 paid on the first anniversary, subject to continued employment).
- Equity Grant: Option to purchase 325,000 shares of common stock, vesting over four years (25% cliff vesting at one year, then monthly).
- Severance: 12 months of base salary and COBRA reimbursement upon termination without Cause or resignation for Good Reason. In the event of a Change in Control within 12 months, severance increases to 15 months of salary plus bonus, with accelerated equity vesting.
Former CFO Transition Compensation (Marc Grasso):
- Advisor Period: Continues to receive current salary and benefits through August 1, 2026.
- Severance Package: 12 months of base salary and COBRA reimbursement upon release of claims.
- Change in Control: If a Change in Control occurs within 3 months after the advisor period, equity vesting requirements are deemed fully satisfied.
Risks and Contingencies: The filing notes that the sign-on bonus for Mr. Martini is repayable in the event of voluntary resignation prior to the first anniversary. Both executives are subject to standard confidentiality, non-compete, and non-solicit covenants.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 325,000 stock options granted to Gregory Martini.
- Confirm the total cash outlay for the sign-on bonus and severance packages relative to the Company's current cash position.
- Review the full text of the Employment Offer Letter (Exhibit 10.1) and Letter Agreement (Exhibit 10.2) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Monitor future filings for any impact on the Company's cash burn rate due to the new executive compensation structure.